• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.351.3-353
• /
• 2002

Oxygen radicals are produced in many pathophysiologic states whether the event is a causal factor of illness or is a result of their progression. Oxygen radicals including superoxide anions. hydrogen peroxide are thought to be involved in a number of type of acute. and chronic pathologic condition in the brain and neural tissue. So the antioxidants have recently received much attention as therapeutic agent for the treatment of neurodegenerative disease. In this study. we describe synthesis of a series of chromenone derivatives as antioxidant agents. The target compounds are designed to include the structural frature of caffeic acid. flavoniod. and focopherol known as antioxidants.

• Journal of Microbiology and Biotechnology
• /
• v.31 no.7
• /
• pp.1022-1027
• /
• 2021

Three compounds were isolated from marine-derived Streptomyces sp. CNQ-031, and their inhibitory activities against monoamine oxidases (MAOs), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-secretase (BACE-1) were evaluated. Compound 1 (5,7-dihydroxy-2-isopropyl-4H-chromen-4-one) was a potent and selective inhibitor of MAO-A, with a 50% inhibitory concentration (IC₅₀) of 2.70 µM and a selectivity index (SI) of 10.0 versus MAO-B. Compound 2 [5,7-dihydroxy-2-(1-methylpropyl)-4H-chromen-4-one] was a potent and low-selective inhibitor of MAO-B, with an IC₅₀ of 3.42 µM and an SI value of 2.02 versus MAO-A. Compound 3 (1-methoxyphenazine) did not inhibit MAO-A or MAO-B. All three compounds showed little inhibitory activity against AChE, BChE, and BACE-1. The K_i value of compound 1 for MAO-A was 0.94 ± 0.28 µM, and the K_i values of compound 2 for MAO-A and MAO-B were 3.57 ± 0.60 and 1.89 ± 0.014 µM, respectively, with competitive inhibition. The 1-methylpropyl group in compound 2 increased the MAO-B inhibitory activity compared with the isopropyl group in compound 1. Inhibition of MAO-A and MAO-B by compounds 1 and 2 was recovered by dialysis experiments. These results suggest that compounds 1 and 2 are reversible, competitive inhibitors of MAOs and can be considered potential therapies for neurological disorders such as depression and Alzheimer's disease.